{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:27:36Z","timestamp":1768339656063,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,6,16]],"date-time":"2005-06-16T00:00:00Z","timestamp":1118880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> Hepatitis\u2003B virus infection is an important public health problem in Turkey. Although hepatitis\u2003B vaccination is regarded as safe and effective for the general population, recommendations for hepatitis\u2003B immunization in patients with Behcet's disease are not clear. The aim of the present study was to elucidate the response of patients with Behcet's disease to hepatitis\u2003B vaccination and to determine whether hepatitis\u2003B vaccination has any adverse effects on the course of the disease.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Thirteen patients with Behcet's disease and 15 healthy individuals were enrolled into a prospective study. All subjects received the 3\u2010dose series of routine hepatitis\u2003B vaccine. Anti\u2010hepatitis\u2003B surface response was evaluated 1\u20133\u2003months after the third dose of vaccine.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The responder rates for patient and control groups were 12\/13 (92.8%) and 14\/15 (93.8%), respectively. Statistical analysis showed no significant difference between the two groups in terms of both the responder rates and mean antibody titers.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> These preliminary findings might suggest that the majority of patients with Behcet's disease develop protective antibody response after hepatitis\u2003B vaccination and that the immune response against hepatitis\u2003B surface antigen is adequate, efficient and intact.<\/jats:p><jats:p>\u00a9 2005 Blackwell Publishing Asia Pty Ltd<\/jats:p>","DOI":"10.1111\/j.1440-1746.2005.03903.x","type":"journal-article","created":{"date-parts":[[2005,8,31]],"date-time":"2005-08-31T15:52:11Z","timestamp":1125503531000},"page":"1508-1511","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Response to vaccination against hepatitis\u2003B in patients with Behcet's disease"],"prefix":"10.1111","volume":"20","author":[{"given":"EMEL","family":"ERKEK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ERGIN","family":"AYASLIOGLU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AYHAN BULENT","family":"ERKEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GULCAN SAYLAM","family":"KURTIPEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YETER","family":"BAGCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,31]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(200007)35:1<47::AID-MPO8>3.0.CO;2-N"},{"key":"e_1_2_5_3_2","first-page":"160","article-title":"HAV, HBV and HCV seroconversion rates according to age and genders in Kirikkale region of Turkey","volume":"8","author":"Kaygusuz S","year":"2003","journal-title":"Viral Hepat."},{"key":"e_1_2_5_4_2","unstructured":"WinkelsteinA.Hepatitis B vaccination. Transfusion Medicine Update. April 2004. Available from URL:http:\/\/www.itxm.org\/Archive\/tmu5\u201094.htm"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00354-0"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310134"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01560-7"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(98)00563-8"},{"key":"e_1_2_5_9_2","first-page":"1369","article-title":"Effects of interleukin\u20102 on hepatitis B vaccination in uraemic patients","volume":"344","author":"Pol S","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540310008410"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00251.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01893.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410020730"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(99)00013-9"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.350"},{"key":"e_1_2_5_16_2","first-page":"179","volume-title":"Viral Hepatitis","author":"Tekeli E.","year":"2003"},{"key":"e_1_2_5_17_2","first-page":"1078","article-title":"Criteria for diagnosis of Behcet's disease","volume":"335","author":"International Study Group for Behcet's Disease.","year":"1990","journal-title":"Lancet"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00313-X"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549409008621"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000189357"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.10.978"},{"key":"e_1_2_5_22_2","first-page":"251","article-title":"Investigation on the efficacy of intradermal hepatitis B vaccination","volume":"5","author":"Doyuk E","year":"2000","journal-title":"Flora"},{"key":"e_1_2_5_23_2","first-page":"117","article-title":"A case showing symptoms similar to systemic rheumatoid arthritis after hepatitis B vaccination","volume":"16","author":"Ozkinay F","year":"2002","journal-title":"Turkish J. Infec."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<468::AID-ANR32>3.0.CO;2-K"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100720070025"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00533-2"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6947.94"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1999.0346"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2005.03903.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2005.03903.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T09:01:26Z","timestamp":1697360486000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2005.03903.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,31]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1440-1746.2005.03903.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2005.03903.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,31]]},"assertion":[{"value":"2005-08-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}